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1.1 Abstract
Although many anti cancer therapies are successful in killing a large percentage of tumour cells
when initially administered, the evolutionary dynamics underpinning tumour progression mean
that often resistance is an inevitable outcome, allowing for new tumour phenotypes to emerge that
are unhindered by the therapy. Research in the field of ecology suggests that an evolutionary double
bind could be an effective way to treat tumours. In an evolutionary double bind two therapies are
used in combination such that evolving resistance to one leaves individuals more susceptible to
the other. In this paper we present a general evolutionary game theory model of a double bind to
study the effect that such approach would have in cancer. Furthermore we use this mathematical
framework to understand recent experimental results that suggest a synergistic effect between a
p53 cancer vaccine and chemotherapy. Our model recapitulates the experimental data and provides
an explanation for its effectiveness based on the commensalistic relationship between the tumour
phenotypes.
Keywords: Evolutionary Game Theory, Evolutionary Double Bind, Mathematical Modelling,
Immunotherapy, Chemotherapy, Combination therapy, comensalism
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1.2 Introduction
Cancer is known to be an evolutionary disease [1]. One of the most negative aspects of the evo-
lutionary nature of cancer is that tumours can evolve resistance to anti-cancer treatments. It has
recently been suggested that we should consider therapies that exploit evolutionary dynamics rather
than fail because of them. One such therapy maybe to exploit an evolutionary double bind, which
in the context of cancer can be understood as a therapy in which adaptation to it represents a
significant fitness cost [2]. This cost could represent a number of things, such as a lower prolif-
eration rate to minimise exposure to drugs that target mitosis, the realocation of resources away
from proliferation in order to obtain resistance or switching to alternative less efficient pathways
that are not targeted. Combination therapies, by which more than one treatment is administered
have the potential to hinder the evolution of resistance as tumours need to adapt to each treatment
independently and resistance to one treatment might make resistance to the other more difficult.
In this sense combination therapies are potentially an ideal approach to facilitate an evolutionary
double bind, where adaptation to one treatment would leave resistant tumour cells more susceptible
to another treatment than the original population.
Its generally well accepted now that cancer consists of multiple populations that are phenotyp-
ically (and genotypically) distinct. This inherent heterogeneity that all cancers appear to exhibit is
one of the central reasons why resistance emerges in the first place. Since a mono-clonal population
that consisted of phenotypically identical cells would be far easier to target therapeutically than
one that consists of a heterogeneous mix of many competing phenotypes. Also, such heterogeneity
could allow for preexisting resistance as opposed to de novo resistance. Regardless of the precise
mechanism of resistance, reducing heterogeneity in a cancer population should make it a more
treatable disease. However, we must be cautious as treatments that manipulate this heterogeneity
may select more aggressive phenotype rather than weaker ones [3]. If it is possible to exploit an
evolutionary double bind we will naturally circumvent this problem.
In this paper we introduce a general theoretical framework to study the potential of evolutionary
double binds based on combination therapies as a cancer treatment. This framework uses evolu-
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tionary game theory (EGT), a mathematical tool that has been traditionally used in evolutionary
ecology [4] and more recently in mathematical oncology [5, 6, 7, 8, 9, 10]. This modelling tool has
potential to provide insights into the evolutionary dynamics of cancer when a combination therapy
is used. Importantly EGT can help explore the role of tumour cell interactions in the emergence
of resistance. More specifically we have utilized an EGT model to understand how chemother-
apy can improve the efficacy of a p53 vaccine as has been reported by Antonia, Gabrilovich and
colleagues[11, 12].
1.3 A general model of an evolutionary double bind
We consider three different populations and two different treatments. For simplicity the treatments
will be referred to as A and B. The populations are S, susceptible to both treatments, RA that
is completely resistant to treatment A but susceptible to treatment B and RB that is resistant to
treatment B and susceptible to treatment A. The cost of resistant is determined by cA and cB and
is assumed to be a fixed cost affecting the fitness of the phenotypes RA and RB respectively. The
cost of treatment A to those phenotypes that are non resistant (i.e.: S and RB) is a function of
time, dA, that is a given constant value when the drug is applied and zero when it is not. The drug
B has been modelled in the same way but affecting only S and RA. The total population is made of
these three phenotypes with a proportion pA of drug A resistant cells, pB of drug B resistant cells
and the rest made of susceptible cells. Under these assumptions, the following equations represent
the fitness of each of the subpopulations:
W (RA) = 1 − cA − αdB(t)
W (RB) = 1 − cB − βdA(t)
W (S) = 1 − dA(t) − dB(t)
Where α and β represent the extra cost of a resistant phenotype being subjected to a different
drug. These constants capture the double bind aspect of the model, since a phenotype resistant to
one drug can be more susceptible to the other.
Given that the average fitness (W¯ ) in the population can be defined as:
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W¯ = pA ∗W (RA) + pB ∗W (RB) + (1 − pA − pB) ∗W (S)
the proportion p of a given phenotype i in the tumour population at a given time t then will be
given by:
pt+1 = pt ∗ W (i)W¯
This model assumes that interactions between these populations have no impact on the evo-
lution of resistance but arguably, the fitness of each of these three populations could change as a
result of those interactions. For instance, assuming that space and nutrients are scarce, a resistant
phenotype interacting with susceptible cells will be better off than the same cell interacting with
equally resistant cells as in the first case it would have easier access to nutrients and space re-
quired for proliferation. This and other hypothetical mechanisms for resistance, like paracrine ones
that could affect phenotypes that do not produce them, could be further explored with a matrix
based approach. Using a matrix approach we can explore how the interactions between different
phenotypes impacts their fitness. The following table enhances the previously described model by
describing how interactions between phenotypes influence the susceptibility of cells to treatments
and thus potentially improve their fitness:
Table 1.1. Payoff table of the general model
RA RB S
RA 1 − cA − αdB(t) 1 − cA − αdB(t) +X(t) 1 − cA − αdB(t)
RB 1 − cB − βdA(t) + Y (t) 1 − cB − βdA(t) 1 − cB − βdA(t)
S 1 − dA(t) − dB(t) 1 − dA(t) − dB(t) 1 − dA(t) − dB(t)
where X(t) is the extra benefit/cost to RA cells interacting with cells susceptible to drug A when
drug A is being delivered. Correspondingly, Y (t) is the extra benefit/cost for RB when interacting
with drug B sensitive cells when drug B is being administered. From this table we can define the
fitness equation of each population as follows:
W (RA) = 1 − cA − αdB(t) + (1 − pA)X(t) (1.1)
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W (RB) = 1 − cB − βdA(t) + (1 − pB)Y (t) (1.2)
W (S) = 1 − dA(t) − dB(t) (1.3)
1.4 p53 cancer vaccine and chemotherapy as an example of an
evolutionary double bind
Cancer immunotherapy is a significant field of cancer research, however, it has not yet been able
to achieve its real potential as a result of low efficacy. Recent studies by Antonia, Gabrilovich and
colleagues [11, 12] suggest that a p53 vaccine [13] could have its efficacy improved if administered
after chemotherapy. The specific reasons for this are unknown but the authors suggest that the
application of drugs such Doxorubicin, Paclitaxel (apoptosis by affecting microtubules) and Cis-
platin (death by DNA crosslinking) sensitises the tumour cells to cytotoxic T cells from the immune
system.
Antonia et al performed a clinical trial at the Moffitt cancer center that can, in retrospect,
be viewed as a potential test of the double bind concept [12]. . The primary goal of the trial was
to test a new cancer vaccine that used dendritic cells transduced with the wild-type p53 gene.
P53 is a tumour suppressor gene that plays a critical role in cellular growth and differentiation.
It is mutated in about 90% of small cell lung cancers. Mutant p53, unlike the wild type, has a
relatively long half life. Thus while the p53 protein is present in low levels in normal cells the
mutant protein remains in fairly large concentrations in most SCL cells. Twenty-nine patients with
small cell lung cancer (SLC) who failed first line therapy were treated. Evidence of a p53-specific T
cell response was observed in 57% of the vaccinated patients (Figure 1.1). However, only 1 patient
exhibited a partial tumour response (i.e. decrease in the size of a tumour Figure 1.1). Fortunately,
the authors continued to follow the patients after the exited from the study. They found that
subsequent treatment with chemotherapy produced a response rate of 62% (compared to historical
controls of less than 5%). Interestingly, those patients who exhibited an immunologic response to the
vaccine were the more likely to respond to chemotherapy than those that did not (Figure 1.1). These
6 David Basanta, Robert A. Gatenby, and Alexander R. A. Anderson
results indicate that either the adaptive response to the p53 vaccine (perhaps by down-regulation
of p53) left the cells more vulnerable to chemotherapy or, alternatively, the chemotherapy rendered
the tumour cells more vulnerable to immune attack. In a follow-up study (JCI) performed in mice,
this group found that chemotherapy (specifically paclitaxel, cisplatin, and doxorubicin) increased
tumour susceptibility by making tumour cells more permeable to granzyme B. These results support
a role for chemotherapy as a sensitizer to immunotherapy. However, the rapid decline in immune
activity following cessation of the vaccination trial (Figure 1.1) suggests that other mechanism may
play a role.
In the remainder of this paper we will use a more specific version of our general model to
understand the evolutionary dynamics that make particular types of combination therapies more
effective than others. Using the papers by Antonia, Gabrilovich and colleagues [11, 12, 13] as
primary motivation, we will assume three different tumour populations: regular tumour cells that are
susceptible to both the p53 vaccine and chemotherapy (S), cells that are resistant to chemotherapy
(C) and cells resistant to the p53 vaccine (I). C and I cells have to pay a relatively small cost of
resistance (Cc and Ci respectively) which means that C cells do not have to pay any fitness cost as
a result of chemotherapy and that I cells do not pay any fitness cost regardless of the concentration
of t-cells (whose efficacy is increased by the p53 vaccine). Both chemotherapy and the p53 vaccine
represent a fitness cost to the susceptible cells (S and I in the case of chemotherapy and S and C
in the case of the p53 vaccine) only during the time they are applied to the tumour. One important
difference between the chemo-resistant population C and the immuno-resistant population I is that
we assume that C have an autocrine type of resistance whereas the I cells evade the immune cells
in a paracrine manner which also helps cells susceptible to the immune system interacting with I
cells. The modified payoff table is the following:
Table 1.2. Payoff table of the p53 vaccine + chemotherapy game
C I S
C 1 − Cc − αdI(t) 1 − Cc − αdI(t)/2 1 − Cc − αdI(t)
I 1 − Ci − βdC(t) 1 − Ci − βdC(t) 1 − Ci − βdC(t)
S 1 − dC(t) − dI(t) 1 − dC(t) − dI(t)/2 1 − dC(t) − dI(t)
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For simplicity we left α and β as constants and equal to 1.1. The treatments dI(t) and dC(t) are
Heaviside step functions multiplied by a cost in the range [0:1]. This value and the duration of the
step will be variables to characterise the treatment. Under these circumstances the average tumour
cell fitness is the following:
W¯ = pC ∗W (C) + pI ∗W (I) + (1 − pC − pI) ∗W (S) (1.4)
1.5 How timing affects the effectiveness of the treatment
We first validated the mathematical model using the results published by Antonia and colleagues
[11, 12]. Figure 1.2 shows the difference in results when chemotherapy is applied first in contrast to
when it is applied second. In the first case (1.2 top left) the p53 vaccine is administered first which
results in an steady increase of the I population and a dramatic reduction of the S population.
After 60 timesteps the p53 vaccine stops being active and chemotherapy is applied after which the
tumour almost entirely consists of C cells. In the second case (1.2 top right) the first treatment is
chemotherapy which selects for C cells driving the other two populations towards extinction. Figure
1.2 bottom shows the difference in average tumour cell fitness between the two therapies. To make
this comparison the figure shows the average fitness W¯ defined by equation 1.4. Here we assume
that the average tumour fitness W¯ correlates with the growth of the tumour, based on the fact that
this fitness, in the evolutionary sense, is a measure of long term proliferation. By comparing the
different impact of the two therapies on tumour fitness we can see why applying chemotherapy first
is better (since it results in a lower tumour fitness and slower growth). These results are consistent
with those of Antonia and suggest that the application of chemotherapy prior to the p53 vaccination
would have a larger impact on the fitness of the tumour and therefore provide a better therapeutic
strategy.
The benefit, of course, in using a simple mathematical model to investigate these dynamics is
that we can explore a variety of protocols characterised by order, intensity and duration both quickly
and cheaply allowing us to easily determine which protocols are the most effective. Figure 1.3 shows
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how the predicted average fitness changes as a function of the protocol order. Treatments in which
chemotherapy is applied first show that increasing the penalty for chemotherapy and the p53 vaccine
has a profound impact on the overall fitness of the tumour. Furthermore, neither chemotherapy nor
the p53 vaccine on their own is sufficient to impact the tumour fitness. Results also suggest that
applying chemotherapy first, in general, has a higher impact on the tumour fitness. Therefore a
higher cost of chemotherapy or a longer exposure to it always results in a less fit tumour.
The situation is different if the p53 vaccine is given before chemotherapy (reversing the order
researched by Antonia and colleagues [12]). Here the results suggest that poorer tumour fitness is
not necessarily the result of big penalties for chemotherapy and the vaccine (as was the case when
chemotherapy is given first). In this case better results are generally obtained when the p53 vaccine
is applied for longer period of time.
In order to gain a better a better understanding of the evolution of the tumour under these
treatments we studied in more detail a number of scenarios. Figure 1.4 shows three simulations
where we kept the cost of cells susceptible to chemotherapy to a constant (0.4) and changed the
cost of cells susceptible to the p53 vaccine (0.2, 0.3 and 0.4). The results show how a high, but not
too high, value of the p53 vaccine cost results in a less heterogeneous tumour. On the other hand
figure 1.5 shows three different simulations where the heterogeneity of the tumour is not affected
by the treatments. In this case chemotherapy is applied first for a duration of 25 time steps and
relatively low cost (0.2) followed by the p53 vaccine for 75 time steps with varying degrees of cost
(0.2, 0.3 and 0.4).
1.6 Discussion: reducing heterogeneity
We have developed a general model of the evolutionary double bind and applied this model to
investigate the role a double bind might play in a combination therapy involving chemotherapy and
a p53 vaccine. The model is general enough that it could be used to study evolutionary dynamics
of double bind in the context of somatic evolution (as well as other evolutionary contexts). The
model is also simple requiring only a few parameters that characterise, the cost of resistance to
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the vaccine and chemotherapy, the cost of susceptibility to either therapy and the cost/benefit
of susceptible cells interacting with resistant ones when a given treatment is administered. The
results show that the model readily recapitulates the observed experimental behaviour when using
combination therapies based on immuno- and chemo-therapies. However, the model can delve deeper
into the treatment dynamic and predicts how different scheduling and dosage will impact tumour
heterogeneity and fitness. As with all mathematical models, a number of caveats apply: we assume
a homogeneously mixed population. We assume only three relevant tumour subpopulations and
that these populations do not change over time (e.g. by become more efficient at being resistant).
Given the timescales involved (days to weeks) it is unlikely that new genetic mutations would allow
the existing populations to change their phenotype significantly.
Despite its simplicity, the model illustrates the importance of understanding the role of cell-cell
interactions in cancer. Usually these interactions are understood to be competitive in nature but the
types of interactions in a tumour can be more complex than that [14]. In the combination therapy
example (p53 vaccine and chemotherapy) the relationship between the susceptible and chemo-
resistant phenotypes on one hand and the p53 vaccine resistant phenotype on the other seems to
correspond to a comensalistic relationship by which the latter provides some degree of protection
against the immune system for the former without receiving any reward for that service. That would
explain why targeting cells that are sensitive to chemotherapy first is an effective treatment as it
disrupts the interactions between the vaccine resistant cells and the rest.
The results coming from the scenarios where the p53 vaccine is applied first are less intuitive. Our
results suggest that no single treatment, be it the vaccine or chemotherapy, is sufficient to negatively
impact the fitness of the tumour and thus its growth potential. Although the application of the two
therapies is necessary to obtain results only when the vaccine and chemotherapy are administered
similar amounts of time (50 time steps each) do higher intensity of treatment lead to a less fit
tumour. As shown in 1.3 (top right and top left) sometimes a smaller drug or vaccine intensity can
lead to a smaller tumour fitness. Figure 1.4 shows in detail an example of this counterintuitive result.
If the cost of the p53 vaccine is moderate (0.2) then susceptible populations will have a chance to
survive and thus to recover when the vaccine is no longer active. If we increase this cost (0.3) the
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chemotherapy resistant population is driven beyond the point of recovery, so when chemotherapy
is applied all the remaining populations are susceptible. Nonetheless, if we further increase the cost
(0.4) the result is that the population that disappears during the application of the vaccine is the
sensitive one whereas the chemotherapy resistant, while minimal, is still there. Once the treatment
is switched to chemotherapy it will recover driving up the overall tumour fitness.
The model shows how the order in which the treatments are applied is important. It also suggests
that the amount of time that chemotherapy is active is more important than that of the p53 vaccine.
With regards to protocols where the p53 vaccine is applied first, the results suggest that treatments
where the vaccine has a long term effect on the tumour are more likely to be effective in impacting
the fitness of the tumour. Although protocols that use the p53 vaccine first are usually not as
effective as those that use chemotherapy first they both have in common that the first treatment
should be effective for as long as possible to be efficacious. This is because the role of the first
treatment should be to reduce the heterogeneity of the tumour in order to diminish the chances
of the tumour evolving resistance. Figure 1.5 highlights the importance of the first part of the
treatment. Although chemotherapy prior to the p53 vaccine can yield good results this example
highlights the risk of not applying chemotherapy for long enough. In all the cases, regardless of how
high the cost of chemotherapy for susceptible cells is, the tumour heterogeneity is maintained and
thus little is achieved in reducing the overall tumour fitness.
In the EGT model we presented here, its no accident that we equate directly tumour fitness
and tumour heterogeneity. By reducing heterogeneity (i.e. in this context, knocking out one of the
resistant populations) with the first treatment we can apply a suitably targeted second treatment
to knock out the remaining resistant populations. Unfortunately, the reality might be that there
are multiple subpopulations that would require different drug or treatment strategies to eradicate
them all and of course this is simply impractical. However, if we can harness the power of strategies
such as the evolutionary double bind we may exploit synergistic aspects of multiple treatments and
manage to drive the tumour population to extinction even with highly heterogenous tumours.
The general model we have described here can be used to study other situations where resistance
to a given treatment comes at a cost and where the interactions between tumour cell populations are
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important with regards to their susceptibility to a therapy. A key advantage of the model is its ability
to quickly and easily test multiple combinations of treatments under different schedules and doses
and highlight which should be chosen for experimental testing. This integrated approach to cancer
treatment will not only allow for the development of potentially novel therapies but simultaneously
allow them to be targeted and optimized for a given patient. Critical to this integration, however,
is the feedback between model and experiment. Thus future application of this model must involve
direct collaboration with experimentalists in order to properly parameterise and test model driven
hypothesis.
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by immature myeloid cells, the induction of antiadenoviral
immune responses, etc. In one study, it was not possible to
evaluate all possible mechanisms. Our analysis indicated that
inhibition of overall T cell reactivity and accumulation of
Treg were not associated with failure to develop p53-specific
immune responses. Our data do not necessarily indicate a lack
of involvement of Treg in SCLC. Treg may migrate from periph-
eral blood to the site of the tumors. In addition, because all
patients were treated with platinum-based chemotherapy
8 weeks before the analysis, it is possible that chemother-
apy could have eliminated some of these cells as was previously
reported for cyclophosphamide (34). Investigation is currently
under way to address this issue.
Our data showed a trend in the association between a
decreased presence of mature CD83+ DCs in the peripheral
blood of patients prior to vaccination and a lack of immune
response to the vaccine. These data may point out an important
role of host DCs in the development of antigen-specific
immune responses. Nearly all patients enrolled in the trial
had significantly reduced levels of DC function, suggesting that
improvement of DC function prior to vaccination might be
necessary to achieve improved efficacy of the vaccine.
Patients with ES SCLC had increased levels of immature
myeloid cells, the cells implicated in tumor-associated antigen-
specific immune suppression (21, 22, 35). Importantly, 100%
of patients with normal prevaccine levels of immature myeloid
Fig. 4. Association between immunologic and clinical response to vaccination. A, clinical response to vaccine. A patient with progressive disease in retroperitoneal lymph
nodes (new, and positive on positron emission tomography scan) 2 months after cisplatin/etoposide therapy was treated with three vaccines at the time of progression.
A partial response was observed 6 weeks after the first vaccine administration. Left, an abdominal CTscan done1week prior to the first vaccine shows two enlarged
retroperitoneal lymphnodes (circled, each 2 cm in diameter).Right, 2weeks after the third vaccine, the CTscan showed a >60% reduction in the size of both lesions.B, overall
survival (inmonths) of all 29 patients treated with the vaccine from the time of the first vaccine injection. C, 18 patients who progressed after vaccination and subsequently
received chemotherapy were divided into two groups according to their immunologic response to the vaccine. PD, progressive disease; SD, stable disease; PR, partial
response; CR, complete response (all according to Response Evaluation Criteria in SolidTumors). P values were calculated using Fisher’s exact test.D and E, the results of
IFN-g ELISPOTassay frompatients who developed p53 immune response to vaccination.The background level of nonspecific IFN-g production (ALVAC-control or irrelevant
peptide) was subtracted.The number of spots per 1!105 cells are shown. All measurements were done in quadruplicate.The mean for each sample is shown. Not all
HLA-A2-positive patients were tested bothwith ALVAC-p53 and p53-derived peptide. F, lymphocyte counts (!109/L) in patients who were treatedwith second-line
chemotherapy. Columns, mean; bars, F SD.
www.aacrjournals.org Clin Cancer Res 2006;12(3) February 1, 2006885
p53 CancerVaccinewith Chemotherapy in Patientswith ES SCLC
 American Association for Cancer Research Copyright © 2006 
 on April 21, 2011clincancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/1078-0432.CCR-05-2013
Fig. 1.1. From Antonia et al Clinical Cancer Research. A. A partial response with reduction in the size of
a retroperitoneal lymph node is observed by CT scans following 3 administrations of vaccine. B. Survival
(in months) of the initially treated cohort of 29 patients from the time of the first vaccination injection C.
Results of 18 patients who progressed following vaccination and received subsequent chemotherapy. They
are divided into two groups based on immunologic response to the vaccine. PD, progressive disease; SD,
stable disease; PR, partial response; CR, compl te response. D, the results of IFN-g ELISPOTassay from
patients who developed p53 immune response to vaccination showing serum evidence of an immune response
following the vaccine but a generally fast decline in immune reactivity following completion of the vaccine
treatments.
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p53 first
Chemo. first



Friday, September 2, 11Fig. 1.2. Both simulations chemotherapy had a cost of 0.2 and the p53 vaccine a cost of 0.4. Left Applica-
tion of the p53 vaccine results in a strong selection force for tumour cells that are resistant. After 60 time
steps the application of chemotherapy results in a strong growth for the chemotherapy resistant population
which was never entirely eradicated Right we show the same therapeutic intervention but with a different
order. The initially selected for chemo-resistant population leads to a situation in which the susceptible and
p53 vaccine-resistant populations are virtually eradicated. Bottom The average tumour fitness under the
two treatments.
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p53 vaccine first
Chemotherapy first
50 75
% of time for 1st treatment
25
Cc
Ci
Fig. 1.3. Average tumour fitness. The following plots show the average tumour fitness (in the range [0:1])
after 100 time steps in which the order, dosage and timing of the application of the two treatments is
changed. The first row shows cases in which the p53 vaccine is applied first whereas the second row shows
the results when chemotherapy is applied first. Each column shows the effect of spending 25, 50 and 75
time steps on the first therapy (using the remain time steps for the second). Each of the grids represents
the average tumour fitness after using treatments with an intensity varying between 0 and 0.5.
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Friday, September 2, 11Fig. 1.4. Three simulations where the p53 vaccine is applied first using three different penalties for cells
susceptible to the p53 vaccine Left 0.2. Application of the p53 vaccine results in a strong selection force
for tumour cells that are resistant. After 75 time steps the application of chemotherapy results in a strong
growth for the chemotherapy resistant population which was never entirely eradicated. Centre 0.3. As it
was the case before, the first 75 time steps result in selection of p53 vaccine resistant cells but in this case the
chemotherapy resistant population has been decimated to the extent that is unable to show any noticeable
recovery when chemotherapy is applied. The original population susceptible to the two treatments, although
not entirely eradicated is unable to play a role. Right 0.4. As it was the case previously, after the 75 time
steps of p53 vaccine chemotherapy is applied. In this case the original susceptible population is entirely
eradicated whereas the one that is resistant to chemotherapy, although comparatively very small, manages
to survive until the application of chemotherapy results in a strong selection force for this cell type.Bottom
The average tumour fitness under the three different scenarios.
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Friday, September 2, 11Fig. 1.5. Three simulations where chemotherapy is applied first (0.2) using three different penalties for
cells that are susceptible to the p53 vaccine. Application of chemotherapy results in a strong selection force
for tumour cells that are resistant. After 25 time steps the chemotherapy resistant population has managed
to grow and overtake the other two but significant amounts of sensitive and p53 vaccine resistant remain.
Left 0.2. Centre 0.3. Right 0.4. Bottom The average tumour fitness under the three different scenarios.
